Contract manufacturing and specialty revenues boost Jubilant
This article was originally published in Scrip
Jubilant Organosys has reported an 8.4% jump in revenues to Rs8.96 billion ($183 million) for its first quarter ended June 30th, aided by robust growth in the contract manufacturing and the speciality pharmaceuticals businesses.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.